Interferons and viruses: An evolutionary arms race of molecular interactions

Trends in Immunology

Volumn 36, Issue 3, 2015, Pages 124-138

  Hoffmann, Hans Heinrich ^a   Schneider, William M ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Innate immunity; Interferon subtype; Interferons; Vaccine adjuvants; Viral antagonism; Viruses

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; JANUS KINASE; MESSENGER RNA; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; VACCINE; VIRUS DNA; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; ENDOCYTOSIS; GENE CONTROL; HOST RESISTANCE; INTERFERON PRODUCTION; MOLECULAR INTERACTION; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEIOTROPY; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; VIRUS; CELL LINEAGE; CLASSIFICATION; EVOLUTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; INNATE IMMUNITY; LYMPHOCYTE; PATHOGENICITY; PHYLOGENY; SIGNAL TRANSDUCTION; VIROLOGY;

ADAPTIVE IMMUNITY; BIOLOGICAL EVOLUTION; CELL LINEAGE; GENE EXPRESSION REGULATION; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; INTERFERON TYPE I; INTERLEUKINS; LYMPHOCYTES; PHYLOGENY; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; VIRUSES;

EID: 84924170901     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.01.004     Document Type: Review

References (190)

1. Manry J., et al. Evolutionary genetic dissection of human interferons. J. Exp. Med. 2011, 208:2747-2759.
2. Barber G.N. Cytoplasmic DNA innate immune pathways. Immunol. Rev. 2011, 243:99-108.
3. Iwasaki A. A virological view of innate immune recognition. Annu. Rev. Microbiol. 2012, 66:177-196.
4. Wu J., Chen Z.J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 2014, 32:461-488.
5. Sun L., et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
6. Cantell K., et al. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol. 1981, 78:29-38.
7. Au W.C., et al. Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J. Biol. Chem. 1998, 273:29210-29217.
8. Barnes B.J., et al. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem. 2001, 276:23382-23390.
9. Marie I., et al. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J. 1998, 17:6660-6669.
10. Perry A.K., et al. The host type I interferon response to viral and bacterial infections. Cell Res. 2005, 15:407-422.
11. Hemont C., et al. Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J. Leukoc. Biol. 2013, 93:599-609.
12. O'Neill L.A., et al. The history of Toll-like receptors - redefining innate immunity. Nat. Rev. Immunol. 2013, 13:453-460.
13. Baig E., Fish E.N. Distinct signature type I interferon responses are determined by the infecting virus and the target cell. Antivir. Ther. 2008, 13:409-422.
14. Coccia E.M., et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 2004, 34:796-805.
15. Easlick J., et al. The early interferon alpha subtype response in infant macaques infected orally with SIV. J. Acquir. Immune Defic. Syndr. 2010, 55:14-28.
16. Genin P., et al. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol. Cell. Biol. 2009, 29:3435-3450.
17. Hillyer P., et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunol. Cell Biol. 2012, 90:774-783.
18. Hiscott J., et al. Differential expression of human interferon genes. Nucleic Acids Res. 1984, 12:3727-3746.
19. Izaguirre A., et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 2003, 74:1125-1138.
20. Palmer P., et al. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors. Eur. Cytokine Netw. 2007, 18:108-114.
21. Puig M., et al. TLR9 and TLR7 agonists mediate distinct type I IFN responses in humans and nonhuman primates in vitro and in vivo. J. Leukoc. Biol. 2012, 91:147-158.
22. Szubin R., et al. Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells. J. Interferon Cytokine Res. 2008, 28:749-763.
23. Thomas J.M., et al. Differential responses of plasmacytoid dendritic cells to influenza virus and distinct viral pathogens. J. Virol. 2014, 88:10758-10766.
24. Zaritsky L.A., et al. Tissue-specific interferon alpha subtype response to SIV infection in brain, spleen, and lung. J. Interferon Cytokine Res. 2013, 33:24-33.
25. Siegal F.P., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284:1835-1837.
26. Colonna M., et al. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
27. Frenz T., et al. Independent of plasmacytoid dendritic cell (pDC) infection, pDC triggered by virus-infected cells mount enhanced type I IFN responses of different composition as opposed to pDC stimulated with free virus. J. Immunol. 2014, 193:2496-2503.
28. LaFleur D.W., et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 2001, 276:39765-39771.
29. Fung K.Y., et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013, 339:1088-1092.
30. Xi Y., et al. Role of novel type I interferon epsilon in viral infection and mucosal immunity. Mucosal Immunol. 2012, 5:610-622.
31. Wijesundara D.K., et al. Unraveling the convoluted biological roles of type I interferons in infection and immunity: a way forward for therapeutics and vaccine design. Front. Immunol. 2014, 5:412.
32. Pott J., et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7944-7949.
33. Davidson S., et al. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 2014, 5:3864.
34. Egli A., et al. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg. Microbes Infect. 2014, 3:e51.
35. Cohen B., et al. Ligand-induced association of the type I interferon receptor components. Mol. Cell. Biol. 1995, 15:4208-4214.
36. Jaks E., et al. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 2007, 366:525-539.
37. Lavoie T.B., et al. Binding and activity of all human alpha interferon subtypes. Cytokine 2011, 56:282-289.
38. Piehler J., et al. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 2012, 250:317-334.
39. Schoggins J.W., et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014, 505:691-695.
40. Schoggins J.W., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
41. Levin D., et al. Stochastic receptor expression determines cell fate upon interferon treatment. Mol. Cell. Biol. 2011, 31:3252-3266.
42. Moll H.P., et al. The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. Cytokine 2011, 53:52-59.
43. Thomas C., et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011, 146:621-632.
44. Levin D., et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 2014, 7:ra50.
45. Moraga I., et al. Receptor density is key to the alpha2/beta interferon differential activities. Mol. Cell. Biol. 2009, 29:4778-4787.
46. Gibbert K., et al. Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. PLoS Pathog. 2012, 8:e1002868.
47. Marchetti M., et al. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol. Biol. Cell 2006, 17:2896-2909.
48. Branca A.A., Baglioni C. Down-regulation of the interferon receptor. J. Biol. Chem. 1982, 257:13197-13200.
49. Payelle-Brogard B., Pellegrini S. Biochemical monitoring of the early endocytic traffic of the type I interferon receptor. J. Interferon Cytokine Res. 2010, 30:89-98.
50. Jaitin D.A., et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol. Cell. Biol. 2006, 26:1888-1897.
51. de Weerd N.A., et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1. Nat. Immunol. 2013, 14:901-907.
52. Thomas K.E., et al. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J. Biol. Chem. 2006, 281:31119-31130.
53. Larner A.C., et al. Transcriptional induction by interferon. New protein(s) determine the extent and length of the induction. J. Biol. Chem. 1986, 261:453-459.
54. Malakhova O.A., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 2006, 25:2358-2367.
55. Francois-Newton V., et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE 2011, 6:e22200.
56. Makowska Z., et al. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology 2011, 53:1154-1163.
57. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
58. Perry S.T., et al. STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog. 2011, 7:e1001297.
59. Goh K.C., et al. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999, 18:5601-5608.
60. Kaur S., et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:4808-4813.
61. Uddin S., et al. Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J. Biol. Chem. 1995, 270:15938-15941.
62. Tang X., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
63. Tenoever B.R., et al. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278.
64. Ungureanu D., et al. PIAS proteins promote SUMO-1 conjugation to STAT1. Blood 2003, 102:3311-3313.
65. Wen Z., et al. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
66. Chua K.B., et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000, 288:1432-1435.
67. Lynch M. Evolution of the mutation rate. Trends Genet. 2010, 26:345-352.
68. Chenik M., et al. Translation initiation at alternate in-frame AUG codons in the rabies virus phosphoprotein mRNA is mediated by a ribosomal leaky scanning mechanism. J. Virol. 1995, 69:707-712.
69. Paterson R.G., Lamb R.A. RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts. J. Virol. 1990, 64:4137-4145.
70. Jacques J.P., et al. Paramyxovirus mRNA editing leads to G deletions as well as insertions. EMBO J. 1994, 13:5496-5503.
71. Kulkarni S., et al. Nipah virus edits its P gene at high frequency to express the V and W proteins. J. Virol. 2009, 83:3982-3987.
72. Vidal S., et al. Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity. J. Virol. 1990, 64:239-246.
73. Vidal S., et al. A stuttering model for paramyxovirus P mRNA editing. EMBO J. 1990, 9:2017-2022.
74. Childs K.S., et al. Mechanism of mda-5 inhibition by paramyxovirus V proteins. J. Virol. 2009, 83:1465-1473.
75. Kato H., et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205:1601-1610.
76. Hornung V., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
77. Pichlmair A., et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
78. Goubau D., et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 2014, 514:372-375.
79. Childs K., et al. Mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 2007, 359:190-200.
80. Childs K., et al. Paramyxovirus V proteins interact with the RNA helicase LGP2 to inhibit RIG-I-dependent interferon induction. J. Virol. 2012, 86:3411-3421.
81. Parisien J.P., et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDA5 and LGP2. J. Virol. 2009, 83:7252-7260.
82. Satoh T., et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1512-1517.
83. Hale B.G., et al. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89:2359-2376.
84. Gack M.U., et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009, 5:439-449.
85. Gack M.U., et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007, 446:916-920.
86. Rajsbaum R., et al. Species-specific inhibition of RIG-I ubiquitination and IFN induction by the influenza A virus NS1 protein. PLoS Pathog. 2012, 8:e1003059.
87. Oshiumi H., et al. Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J. Biol. Chem. 2009, 284:807-817.
88. Oshiumi H., et al. The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection. Cell Host Microbe 2010, 8:496-509.
89. Hou F., et al. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011, 146:448-461.
90. Yang Y., et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7253-7258.
91. Li X.D., et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17717-17722.
92. Meylan E., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
93. Wei C., et al. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J. Immunol. 2010, 185:1158-1168.
94. Lu L.L., et al. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J. Biol. Chem. 2008, 283:14269-14276.
95. Irie T., et al. Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein. J. Virol. 2012, 86:7136-7145.
96. Shaw M.L., et al. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J. Virol. 2005, 79:6078-6088.
97. Sparrer K.M., et al. Measles virus C protein interferes with beta interferon transcription in the nucleus. J. Virol. 2012, 86:796-805.
98. Haspel R.L., et al. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J. 1996, 15:6262-6268.
99. Lee C.K., et al. Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity. J. Biol. Chem. 1997, 272:21872-21877.
100. Parisien J.P., et al. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology 2001, 283:230-239.
101. Andrejeva J., et al. The p127 subunit (DDB1) of the UV-DNA damage repair binding protein is essential for the targeted degradation of STAT1 by the V protein of the paramyxovirus simian virus 5. J. Virol. 2002, 76:11379-11386.
102. Leung-Pineda V., et al. DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 2009, 69:2630-2637.
103. Lin G.Y., et al. The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein. Virology 1998, 249:189-200.
104. Sarikas A., et al. The cullin protein family. Genome Biol. 2011, 12:220.
105. Didcock L., et al. The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J. Virol. 1999, 73:9928-9933.
106. Paulson M., et al. Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. J. Biol. Chem. 1999, 274:25343-25349.
107. Parisien J.P., et al. STAT2 acts as a host range determinant for species-specific paramyxovirus interferon antagonism and simian virus 5 replication. J. Virol. 2002, 76:6435-6441.
108. Ashour J., et al. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 2010, 8:410-421.
109. Ashour J., et al. NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 2009, 83:5408-5418.
110. Mazzon M., et al. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 2009, 200:1261-1270.
111. Ulane C.M., et al. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J. Virol. 2003, 77:6385-6393.
112. Yokosawa N., et al. C-terminal region of STAT-1alpha is not necessary for its ubiquitination and degradation caused by mumps virus V protein. J. Virol. 2002, 76:12683-12690.
113. Ho H.H., Ivashkiv L.B. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J. Biol. Chem. 2006, 281:14111-14118.
114. Zhong Z., et al. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.
115. Buettner R., et al. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8:945-954.
116. Levy D.E., Lee C.K. What does Stat3 do?. J. Clin. Invest. 2002, 109:1143-1148.
117. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
118. Rodriguez J.J., et al. Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J. Virol. 2002, 76:11476-11483.
119. Rodriguez J.J., et al. Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. J. Virol. 2003, 77:11842-11845.
120. Meyer T., et al. Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J. 2002, 21:344-354.
121. Rodriguez J.J., et al. Identification of the nuclear export signal and STAT-binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. J. Virol. 2004, 78:5358-5367.
122. Shaw M.L., et al. Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J. Virol. 2004, 78:5633-5641.
123. Caignard G., et al. Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 2009, 383:112-120.
124. Palosaari H., et al. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J. Virol. 2003, 77:7635-7644.
125. Caignard G., et al. Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology 2007, 368:351-362.
126. Takeuchi K., et al. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett. 2003, 545:177-182.
127. Yu C.L., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83.
128. Garcin D., et al. The amino-terminal extensions of the longer Sendai virus C proteins modulate pY701-Stat1 and bulk Stat1 levels independently of interferon signaling. J. Virol. 2003, 77:2321-2329.
129. Gotoh B., et al. The STAT2 activation process is a crucial target of Sendai virus C protein for the blockade of alpha interferon signaling. J. Virol. 2003, 77:3360-3370.
130. Saito S., et al. Dephosphorylation failure of tyrosine-phosphorylated STAT1 in IFN-stimulated Sendai virus C protein-expressing cells. Virology 2002, 293:205-209.
131. Komatsu T., et al. Sendai virus C protein impairs both phosphorylation and dephosphorylation processes of Stat1. FEBS Lett. 2002, 511:139-144.
132. Schomacker H., et al. The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome. PLoS ONE 2012, 7:e28382.
133. Reid S.P., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 2006, 80:5156-5167.
134. Reid S.P., et al. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 2007, 81:13469-13477.
135. Valmas C., Basler C.F. Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 2011, 85:4309-4317.
136. Valmas C., et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 2010, 6:e1000721.
137. Cheon H., et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 2013, 32:2751-2763.
138. Abate D.A., et al. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J. Virol. 2004, 78:10995-11006.
139. Melroe G.T., et al. Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J. Virol. 2004, 78:8411-8420.
140. Cloutier N., Flamand L. Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J. Biol. Chem. 2010, 285:7208-7221.
141. Cunningham C., et al. Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. J. Gen. Virol. 2003, 84:1471-1483.
142. Neipel F., et al. Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?. J. Virol. 1997, 71:4187-4192.
143. Russo J.J., et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U.S.A. 1996, 93:14862-14867.
144. Burysek L., et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J. Virol. 1999, 73:7334-7342.
145. Lin R., et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 2001, 20:800-811.
146. Wang J.T., et al. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J. Virol. 2009, 83:1856-1869.
147. Geiger T.R., Martin J.M. The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells. J. Virol. 2006, 80:11638-11650.
148. Ronco L.V., et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12:2061-2072.
149. Hong S., et al. Suppression of STAT-1 expression by human papillomaviruses is necessary for differentiation-dependent genome amplification and plasmid maintenance. J. Virol. 2011, 85:9486-9494.
150. Li S., et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18:5727-5737.
151. Barnard P., McMillan N.A. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259:305-313.
152. Juang Y.T., et al. Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9837-9842.
153. Yang X.J., et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324.
154. Look D.C., et al. Direct suppression of Stat1 function during adenoviral infection. Immunity 1998, 9:871-880.
155. Davis B.S., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 2001, 75:4040-4047.
156. Goubau D., et al. Cytosolic sensing of viruses. Immunity 2013, 38:855-869.
157. Ishii K.J., Akira S. Innate immune recognition of nucleic acids: beyond toll-like receptors. Int. J. Cancer 2005, 117:517-523.
158. Kawasaki T., et al. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity. Immunol. Rev. 2011, 243:61-73.
159. Caskey M., et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208:2357-2366.
160. Stahl-Hennig C., et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5:e1000373.
161. Patole P.S., et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 2005, 16:1326-1338.
162. Shukla N.M., et al. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. J. Med. Chem. 2010, 53:4450-4465.
163. Fidock M.D., et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin. Pharmacol. Ther. 2011, 89:821-829.
164. Xiang A.X., et al. Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids 2007, 26:635-640.
165. Hamm S., et al. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J. Immunotoxicol. 2009, 6:257-265.
166. Dalpke A.H., et al. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002, 106:102-112.
167. Krug A., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:2154-2163.
168. Krieg A.M., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
169. Cooper C., Mackie D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV safety and efficacy. Expert Rev. Vaccines 2011, 10:417-427.
170. Boule M.W., et al. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 2004, 199:1631-1640.
171. Christensen S.R., et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 2005, 202:321-331.
172. Deng G.M., et al. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat. Med. 1999, 5:702-705.
173. Zipris D., et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J. Immunol. 2007, 178:693-701.
174. Ablasser A., et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 2013, 498:380-384.
175. McWhirter S.M., et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J. Exp. Med. 2009, 206:1899-1911.
176. Prantner D., et al. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J. Biol. Chem. 2012, 287:39776-39788.
177. Roberts Z.J., et al. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J. Exp. Med. 2007, 204:1559-1569.
178. Conlon J., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 2013, 190:5216-5225.
179. Yan H., et al. 3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection. Biochem. Biophys. Res. Commun. 2009, 387:581-584.
180. Ebensen T., et al. Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 2011, 29:5210-5220.
181. Gibbert K., et al. IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br. J. Pharmacol. 2013, 168:1048-1058.
182. Pestka S., et al. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
183. Schroder K., et al. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75:163-189.
184. Kotenko S.V., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69-77.
185. Prokunina-Olsson L., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013, 45:164-171.
186. Sheppard P., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
187. Sommereyns C., et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, 4:e1000017.
188. Schneider W.M., et al. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 2014, 32:513-545.
189. Poritt R.A., Hertzog P.J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 2015, 10.1016/j.it.2015.02.002.
190. Schreiber G., Piehler J. The molecular basis for functional plasticity in type I interferon signaling. Trends Immunol. 2015, 10.1016/j.it.2015.01.002.